Recently, the "Jinan City to support the high-quality development of innovative medicine measures (2024)" (hereinafter referred to as the "measures") issued, focusing on the field of innovative medicine launched eight aspects of 33 measures, open up the whole industry chain, for the biomedical and health industry innovation and development further.
The industry revenue was nearly 223 billion yuan
Biomedical and health industry is one of the four leading pillar industries in Jinan. Jinan has issued a number of policy documents to support industrial development. In 2023, there are 603 enterprises above the industrial scale, with a revenue of 222.96 billion yuan.
A number of influential leading backbone enterprises have grown up. There are 86 enterprises in the pharmaceutical manufacturing industry and 41 enterprises in the medical device manufacturing industry. It has a group of leading backbone enterprises such as Qilu Pharmaceutical, Huaxi Biological, Boke Holding, Freida Biological, Hongjitang, Yinfeng Biological and so on. Among them: Qilu Pharmaceutical ranks fifth in the national Top 100 pharmaceutical industry, Huaxi Biological is the world's largest hyaluronic acid production and research and development enterprises, hyaluronic acid global market share of more than 40%.
A number of high-level R&D and innovation platforms have been set up. It has built 12 national R&D platforms, 219 provincial innovation platforms, and 87 municipal key laboratories. Innovative products leading domestic, with two class 1 innovative drugs. The city has a total of 1333 drug approval numbers, 1397 Class 2 and Class 3 medical device approvals, 279 drugs through consistency evaluation, ranking first in Shandong Province.
A number of core products with strong market competitiveness have been highlighted. The global market share of more than 20 raw materials such as cephalosporin and batan series is the first; 22 preparation products in the international market share first, more than 60 preparation products in the domestic market share first. Jinan has 73 first or exclusive products listed in the country, and bevacizumab biosimilar drugs are the first in the country to be industrialized.
The spatial layout of "double core, double valley and multiple gardens" is gradually becoming a trend. It has formed a development pattern led by the "dual core" of Jinan High-tech Zone and Jinan International Medical Center, supported by the "double valley" of the world's hyaluronic acid Valley and the "double Valley" of Luzhong International Biological Valley, and the "multi-park" of key parks such as Qilu Pharmaceutical Biomedical Industrial Park. The city's eight key parks achieved revenue of 28.88 billion yuan in 2023, an increase of 11.2%.
The industrial ecology enriched in resource elements is improving day by day. The city has 17 medical colleges and universities, 28 national key disciplines and clinical key disciplines, and 30 drug clinical trial bases. Lead the establishment of the provincial capital economic circle bio-pharmaceutical industry alliance to promote the coordinated development of the provincial capital economic circle industry.
Real money promotes industrial development
"Innovative medicine" is the frontier of biomedicine and health industry. Focusing on this field, Jinan focuses on the whole chain of high-quality development of innovative medicine such as clinical research, medical device approval, and clinical application, and puts forward "eight supports", including building a strong carrier platform to support the quality and efficiency of innovative clinical research; Optimize the work flow and support the accelerated review and approval of innovative medical devices; Strengthen the guarantee mechanism to support the clinical application of innovative medicine; Strengthen supporting services to support the expansion of innovative pharmaceutical application channels; Smooth circulation channels, support innovative medicine to carry out international trade; Enrich application scenarios, support health and medical data to enable pharmaceutical innovation; Strengthen financial support to support diversified financing of pharmaceutical enterprises; Strengthen factor guarantee, support pharmaceutical enterprises to improve the quality and efficiency of development.
The "Several measures" proposed to create the Jinan Branch Center for drug evaluation and verification, promote the "supplementary application review time limit" of Jinan listed drugs from 200 days to 60 days, reduce the average inspection time limit of passive medical devices from 90 working days to 60 days, and reduce the active products from 130 working days to 90 days.
To solve the difficulty of admission of innovative drugs, the "Several measures" proposed to compress the start-up time of clinical trials to less than 28 weeks, and support the construction and development of research hospitals. At the same time, use medical insurance payments to leverage the development of innovative medicine, such as eligible medical insurance payments, including more innovative drugs into the scope of "Qilu insurance" protection, and encourage innovative medical devices to be included in commercial insurance.
In recent years, focusing on the five major fields of biomedicine, traditional Chinese medicine, medical equipment, medical beauty anti-aging, special medical food, Jinan has formed a relatively complete industrial chain group from basic research, clinical trials, manufacturing, sales and service to medical health care. In order to further promote industrial development, the "Several measures" put forward a lot of real money and silver support, such as special medical food each approval award of 1 million yuan, up to 3 million yuan; The independent innovation of medical beauty anti-aging products successfully listed will be rewarded 100,000 yuan each, up to 500,000 yuan; According to the listing process of enterprises to give subsidies of up to 10 million yuan in stages.
The above content comes from the Internet, if there is infringement contact delete.